Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
暂无分享,去创建一个
[1] D. Davies,et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade , 2008, British Journal of Cancer.
[2] G. Mariani,et al. Multidrug resistance in cancer: its mechanism and its modulation. , 2007, Drug news & perspectives.
[3] C. Contag,et al. Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice , 2007, Proceedings of the National Academy of Sciences.
[4] D. Kingston,et al. Taxoids: cancer-fighting compounds from nature. , 2007, Current opinion in drug discovery & development.
[5] Yoshio Hayashi,et al. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. , 2006, Journal of medicinal chemistry.
[6] F. Cailler,et al. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). , 2006, Journal of medicinal chemistry.
[7] J. Rothbard,et al. Molecular Transporters: Synthesis of Oligoguanidinium Transporters and Their Application to Drug Delivery and Real‐Time Imaging , 2006, Chembiochem : a European journal of chemical biology.
[8] S. Dei,et al. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). , 2006, Current drug targets.
[9] C. Contag,et al. Releasable luciferin-transporter conjugates: tools for the real-time analysis of cellular uptake and release. , 2006, Journal of the American Chemical Society.
[10] D. Juric,et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell lines , 2006, Genes, chromosomes & cancer.
[11] Gianni Tognoni,et al. Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.
[12] V. Yang,et al. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. , 2005, Bioorganic & medicinal chemistry letters.
[13] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[14] V. Torchilin. Protein- and peptide-mediated transduction: mechanisms and implications for drug delivery , 2005 .
[15] M. Filipits. Mechanisms of cancer: multidrug resistance , 2004 .
[16] J. Leroux,et al. Micelles in anticancer drug delivery , 2004 .
[17] Julie L Prior,et al. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] Chava Kimchi-Sarfaty,et al. P-glycoprotein: from genomics to mechanism , 2003, Oncogene.
[19] C. Mamot,et al. Liposome-based approaches to overcome anticancer drug resistance. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[20] A. Wolff,et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] Joel A Swanson,et al. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.
[22] G. Gaedicke,et al. Pilot Study of Hydrolytically Activated Paclitaxel Prodrug Therapy in Patients with Progressive Malignancies , 2002 .
[23] D. Aggarwal,et al. Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.
[24] T. Flagg,et al. MDR1 P-glycoprotein Reduces Influx of Substrates without Affecting Membrane Potential* , 2001, The Journal of Biological Chemistry.
[25] K. Pattabiraman,et al. An efficient, scalable synthesis of the molecular transporter octaarginine via a segment doubling strategy. , 2001, Organic letters.
[26] J. Schellens,et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.
[27] C. Rousselle,et al. Doxorubicin-peptide conjugates overcome multidrug resistance , 2001, Anti-cancer drugs.
[28] D. Kingston. Recent advances in the chemistry of taxol. , 2000, Journal of natural products.
[29] J. Verweij,et al. Development of Multidrug-Resistance Convertors: Sense or Nonsense? , 2000, Investigational New Drugs.
[30] D. Kingston. Recent Advances in the Chemistry of Taxol1,2 , 2000 .
[31] S. Mooberry,et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. , 1999, Cancer research.
[32] S. Kuduk,et al. Identification of the domains of photoincorporation of the 3'- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. , 1998, Biochemistry.
[33] L. Mayer. Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies , 1998, Cancer and Metastasis Reviews.
[34] P. Vrignaud,et al. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. , 1996, Journal of medicinal chemistry.
[35] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[36] E. Lazarides,et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.
[37] I. Ringel,et al. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.
[38] L. Vindeløv,et al. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions , 1977, Virchows Archiv. B, Cell pathology.
[39] A. McPhail,et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.
[40] A. Wolff,et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] S. Shaffer,et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. , 2003, Advances in experimental medicine and biology.
[42] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[43] A. Seelig. A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.
[44] J. Beijnen,et al. Taxanes: a new class of antitumor agents. , 1995, Cancer investigation.
[45] M. R. Mejillano,et al. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. , 1992, Journal of medicinal chemistry.